RBF Capital LLC Invests $1.93 Million in Perrigo Company plc $PRGO

RBF Capital LLC purchased a new stake in Perrigo Company plc (NYSE:PRGO) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 180,000 shares of the company’s stock, valued at approximately $1,933,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PRGO. EverSource Wealth Advisors LLC raised its holdings in shares of Perrigo by 116.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock worth $26,000 after acquiring an additional 1,014 shares during the period. Geneos Wealth Management Inc. boosted its holdings in Perrigo by 439.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after purchasing an additional 786 shares during the last quarter. UMB Bank n.a. increased its holdings in shares of Perrigo by 161.5% during the 4th quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock worth $27,000 after buying an additional 1,213 shares during the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Perrigo during the 4th quarter worth approximately $28,000. Finally, CWM LLC raised its position in shares of Perrigo by 230.0% during the 4th quarter. CWM LLC now owns 2,191 shares of the company’s stock valued at $31,000 after buying an additional 1,527 shares during the period. Institutional investors and hedge funds own 95.91% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Weiss Ratings upgraded Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. Zacks Research upgraded Perrigo from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $19.33.

Perrigo Stock Performance

NYSE:PRGO opened at $10.45 on Thursday. Perrigo Company plc has a fifty-two week low of $9.23 and a fifty-two week high of $28.22. The company has a debt-to-equity ratio of 1.45, a quick ratio of 1.59 and a current ratio of 2.72. The company has a 50 day moving average price of $10.57 and a 200 day moving average price of $11.68. The stock has a market capitalization of $1.45 billion, a P/E ratio of -0.80, a PEG ratio of 1.22 and a beta of 0.51.

Perrigo (NYSE:PRGO) last announced its earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The company had revenue of $841.80 million for the quarter, compared to analyst estimates of $1.04 billion. During the same quarter in the previous year, the company earned $0.60 earnings per share. The firm’s quarterly revenue was down 7.2% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Equities research analysts forecast that Perrigo Company plc will post 2.11 EPS for the current year.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.